Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial

被引:86
作者
Beckett, N. [1 ]
Peters, R. [2 ]
Tuomilehto, J. [3 ,4 ]
Swift, C. [5 ]
Sever, P. [6 ]
Potter, J. [7 ]
McCormack, T. [8 ]
Forette, F. [9 ]
Gil-Extremera, B. [10 ]
Dumitrascu, D. [11 ]
Staessen, J. A. [12 ]
Thijs, L. [13 ]
Fletcher, A. [14 ]
Bulpitt, C. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England
[2] Univ London Imperial Coll Sci Technol & Med, Clin Trials Unit, London SW7 2AZ, England
[3] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland
[4] S Ostrobothnia Cent Hosp, Seinajoki, Finland
[5] Kings Coll London, Dept Clin Gerontol, Clin Age Res Unit, London WC2R 2LS, England
[6] Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, London SW7 2AZ, England
[7] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England
[8] Spring Vale Med Ctr, Whitby, ON, Canada
[9] Univ Paris 05, Hop Broca, Paris, France
[10] Dept Med Granada, FAC Med, Granada, Spain
[11] Spitalul Judetean Cluj, Cluj Napoca, Romania
[12] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands
[13] Katholieke Univ Leuven, Studies Coordinating Ctr, Div Hypertens & Cardiovasc Rehabil, Louvain, Belgium
[14] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2012年 / 344卷
关键词
SYSTOLIC HYPERTENSION; BLOOD-PRESSURE; DOUBLE-BLIND; HYVET-COG; DEMENTIA; PROTOCOL; THERAPY; AGE;
D O I
10.1136/bmj.d7541
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertensive treatment. Design One year open label active treatment extension of randomised controlled trial (Hypertension in the Very Elderly Trial (HYVET)). Setting Hospital and general practice based centres mainly in eastern and western Europe, China, and Tunisia. Participants People on double blind treatment at the end of HYVET were eligible to enter the extension. Interventions Participants on active blood pressure lowering treatment continued taking active drug; those on placebo were given active blood pressure lowering treatment. The treatment regimen was as used in the main trial-indapamide SR 1.5 mg (plus perindopril 2-4 mg if required)-with the same target blood pressure of less than 150/80 mm Hg. Main outcome measures The primary outcome was all stroke; other outcomes included total mortality, cardiovascular mortality, and cardiovascular events. Results Of 1882 people eligible for entry to the extension, 1712 (91%) agreed to participate. During the extension period, 1682 patient years were accrued. By six months, the difference in blood pressure between the two groups was 1.2/0.7 mm Hg. Comparing people previously treated with active drug and those previously on placebo, no significant differences were seen for stroke (n=13; hazard ratio 1.92, 95% confidence interval 0.59 to 6.22) or cardiovascular events (n=25; 0.78, 0.36 to 1.72). Differences were seen for total mortality (47 deaths; hazard ratio 0.48, 0.26 to 0.87; P=0.02) and cardiovascular mortality (11 deaths; 0.19, 0.04 to 0.87; P=0.03). Conclusion Very elderly patients with hypertension may gain immediate benefit from treatment. Sustained differences in reductions of total mortality and cardiovascular mortality reinforce the benefits and support the need for early and long term treatment.
引用
收藏
页数:10
相关论文
共 12 条
[1]   Treatment of hypertension in patients 80 years of age or older [J].
Beckett, Nigel S. ;
Peters, Ruth ;
Fletcher, Astrid E. ;
Staessen, Jan A. ;
Liu, Lisheng ;
Dumitrascu, Dan ;
Stoyanovsky, Vassil ;
Antikainen, Riitta L. ;
Nikitin, Yuri ;
Anderson, Craig ;
Belhani, Alli ;
Forette, Francoise ;
Rajkumar, Chakravarthi ;
Thijs, Lutgarde ;
Banya, Winston ;
Bulpitt, Christopher J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) :1887-1898
[2]   Hypertension in the Very Elderly Trial (HYVET) - Protocol for the Main Trial [J].
Bulpitt, C ;
Fletcher, A ;
Beckett, N ;
Coope, J ;
Gil-Extremera, B ;
Forette, F ;
Nachev, C ;
Potter, J ;
Sever, P ;
Staessen, J ;
Swift, C ;
Tuomilehto, J .
DRUGS & AGING, 2001, 18 (03) :151-164
[3]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[4]  
Colvez A, 1996, EPIDEMIOLOGY OLD AGE, P41
[5]   Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes [J].
Kostis, JB ;
Wilson, AC ;
Freudenberger, RS ;
Cosgrove, NM ;
Pressel, SL ;
Davis, BR .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (01) :29-35
[6]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
[7]  
Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]
[8]   A substudy protocol of the hypertension in the very elderly trial assessing cognitive decline and dementia incidence (HYVET-COG) - An ongoing randomised, double-blind, placebo-controlled trial [J].
Peters, R ;
Beckett, N ;
Nunes, M ;
Fletcher, A ;
Forette, F ;
Bulpitt, C .
DRUGS & AGING, 2006, 23 (01) :83-92
[9]   Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial [J].
Peters, Ruth ;
Beckett, Nigel ;
Forette, Francoise ;
Tuomilehto, Jaakko ;
Clarke, Robert ;
Ritchie, Craig ;
Waldman, Adam ;
Walton, Ivan ;
Poulter, Ruth ;
Ma, Shuping ;
Comsa, Marius ;
Burch, Lisa ;
Fletcher, Astrid ;
Bulpitt, Christopher .
LANCET NEUROLOGY, 2008, 7 (08) :683-689
[10]   The effect of treatment based on a diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET) [J].
Peters, Ruth ;
Beckett, Nigel ;
Burch, Lisa ;
de Vernejoul, Marie-Christine ;
Liu, Lisheng ;
Duggan, Joe ;
Swift, Cameron ;
Gil-Extremera, Blas ;
Fletcher, Astrid ;
Bulpitt, Christopher .
AGE AND AGEING, 2010, 39 (05) :609-616